The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is ...
Interested individuals should prepare and submit an application to Christine Battle, Publisher and Vice President, Scientific Publications, AACR via email (
[email protected]) by Monday, ...